Hank Mansbach
Company: 89 Bio
Job title: Chief Medical Officer
Seminars:
3.15 pm Panel Discussion: Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes 3:15 pm
Integrating the design of therapies involving novel mechanisms with new, predictive biomarkers to provide a more precise and efficient approach to drug discovery and development for earlier identification of responders and non-responders Leveraging cutting-edge understanding of MASH pathogenesis to design innovative therapies to target the root causes of the disease for more effective treatments that…Read more
day: Combination & Sequential Therapy Focus Day
11:30 am Leveraging FGF21 Signaling to Target Fibrosis & Metabolic Pathways for More Effective Treatment Development 11:30 am
Using FGF21 therapy as a potent modulator of fibrosis progression and regression across cirrhotic and non-cirrhotic patients Evaluating the effect of FGF21 analogs on hepatic steatosis and inflammation reduction to improve the underlying drivers of fibrosis Examining additive effects when combined with incretin therapies to provide a holistic approach to therapyRead more
day: Combination & Sequential Therapy Focus Day